1 active not recruiting, 1 completed. 1 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Completed 1 |
| Phase 2 | 1 | Completed 1 |
Follow Institutional standard of care: new trials by email Literature Review of Institutional standard of care trials Research Report on Institutional standard of care
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| DECAMP 1 PLUS: Prediction of Lung Cancer Using Noninvasive Biomarkers Institutional standard of care, Biosamples of airway and blood - Pulmonary Disease | Active not recruiting | Boston University | 85 | 2020-08-24 | 2026-04-01 | |
| Evaluation of NanoDoce® in Participants With Urothelial Carcinoma NanoDoce (direct injection), NanoDoce (intravesical instillation) - Visit 2 Instillation, Institutional Standard of Care - Bladder Cancer, Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | NanOlogy, LLC | 36 | 2019-04-02 | 2023-08-14 |
Carcinoma, Transitional Cell (1) · Lung Diseases (1) · Non-Muscle Invasive Bladder Neoplasms (1) · Urinary Bladder Neoplasms (1) · Urogenital Neoplasms (1) · Urologic Neoplasms (1)
Boston University (1) · NanOlogy, LLC (1)
United States (2)
Denise Aberle, MD (1) · Donald Lamm, MD, FACS (1) · Ehab Billatos, MD (1) · George Washko, MD (1)